Amgen Partners with Broad, Mass General on IBD Drug Discovery | GenomeWeb

NEW YORK (GenomeWeb News) – Massachusetts General Hospital, the Broad Institute, and Amgen are collaborating to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease, the partners said today.

While scientists have identified more than 150 regions of the genome that place a person at risk for developing IBD, treatments that make use of this knowledge are "urgently needed," the partners said, noting that recently developed IBD drugs are not always effective and can cause significant side effects in some patients.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.

A cancer researcher retracts 19 articles from one journal for image manipulation, according to Retraction Watch.

Precision medicine has to consider context in addition to genetic mutations in cancer treatment, Medscape reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.